STUDY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLUL

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是评估新药索拉非尼是否对肝癌患者有效。这项研究中的受试者接受了索拉非尼或安慰剂(一种看起来与索拉非尼相同但不含活性药物的片剂)。到目前为止，超过8787名癌症患者单独服用索拉非尼或与其他化疗药物一起治疗几种不同类型的癌症。在回顾了到目前为止从这项研究中收集的数据之后，服用索拉非尼的患者和接受安慰剂(看起来像索拉非尼的糖丸)的患者的总存活率有显著差异。与服用安慰剂的患者相比，服用索拉非尼的患者平均寿命更长。因此，研究的交叉阶段已经开始，在这个阶段，服用索拉非尼的受试者可以选择继续服用索拉非尼。服用安慰剂的受试者可以选择开始服用索拉非尼。这项研究的交叉阶段将继续进行，直到有研究之外的索拉非尼替代治疗可用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to assess if a new drug, sorafenib, is an effective treatment for patients with liver cancer. Subjects in this study received either sorafenib or placebo (a tablet that looks identical to sorafenib but contains no active drug). To date, over 8787 cancer patients have taken sorafenib either as a lone treatment or together with other chemotherapy drugs for several different types of cancer. Following a review of the data collected from this study so far, a significant difference was noticed in the overall survival between patients receiving sorafenib and patients receiving placebo (sugar pill that looks like sorafenib). Those patients taking sorafenib lived longer on average compared to patients taking placebo. As a result the crossover phase of the study has begun where subjects taking sorafenib have been offered the option to continue taking sorafenib. Subjects taking placebo have been offered the option to begin taking sorafenib. This crossover phase of the study will continue until an alternative supply of sorafenib treatment outside of the study is made available.'